Streetbeat News

ICCM

IceCure Medical Ltd

Industry

Medical - Devices

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Open

1.38

Mkt cap

80M

Volume

166K

High

1.44

P/E Ratio

-5.07

52-wk high

1.66

Low

1.38

Div yield

N/A

52-wk low

0.48

An independent study conducted in Spain has validated the safety and effectiveness of IceCure Medical Ltd.'s (NASDAQ:ICCM) ProSense Cryoablation system as an outpatient procedure for breast cancer, with a success rate of 96.8%. The study involved women who declined standard surgery and used ProSense for cryoablation treatment. The study concluded that cryoablation could be an alternative treatment to surgery for breast cancer in patients who reject surgery.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:09 pm

The Federal Reserve has left the key overnight interest rate unchanged at 5.25-5.50% and anticipates one more 25-basis-point rate hike by the end of the year. U.S. stocks traded mixed, with the Dow Jones gaining around 200 points. Steelcase Inc., Cambridge Bancorp, and Fresh Tracks Therapeutics saw significant stock increases, while Seelos Therapeutics, ARS Pharmaceuticals, and IceCure Medical experienced significant drops.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 6:33 pm

The article lists the stocks that gained and lost the most in Wednesday's mid-day session. Among the gainers were MSP Recovery, Digital Transformation Opportunities Corp., Bluejay Diagnostics, Fresh Tracks Therapeutics, and AgriFORCE Growing Systems. Among the losers were Seelos Therapeutics, ARS Pharmaceuticals, Connexa Sports Technologies, Molekule Group, and IceCure Medical.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 6:10 pm

U.S. stocks traded mixed with the Nasdaq Composite turning lower. General Mills Inc reported better-than-expected earnings for its first quarter. Steelcase Inc. reported better-than-expected results for its second quarter. Shares of Cambridge Bancorp surged after the company announced a merger with Eastern Bankshares. Fresh Tracks Therapeutics shares were up after the company announced a plan of liquidation and dissolution. Seelos Therapeutics shares dropped after its SLS-002 Phase II study did not meet the pre-defined primary endpoint. ARS Pharmaceuticals shares were down after the FDA issued a Complete Response Letter regarding its New Drug Application. IceCure Medical shares fell after the FDA denied its De Novo Classification request for breast cancer.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 4:09 pm

The FDA has denied IceCure Medical Ltd's (NASDAQ:ICCM) De Novo Classification request for the ProSense System for breast cancer. This decision does not affect ProSense's FDA-cleared authorization for other indications in the U.S. IceCure is addressing the FDA's response and continues its ICE3 clinical study, expected to be completed in Q1 2024. ICCM shares are down 35.80%.

Portfolio Pulse from Vandana Singh

September 20, 2023 | 2:51 pm

IceCure's shares are trading lower following the FDA's denial of its De Novo Classification request for breast cancer, which was based on interim analysis from its ICE3 study.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:59 pm

IceCure Medical's De Novo classification request for breast cancer, based on interim analysis from its ICE3 study, has been denied by the FDA at this time.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 11:03 am

In the last quarter, Icecure Medical (NASDAQ:ICCM) received four bullish analyst ratings. The average price target is $3.25, implying an upside from the current price of $1.1111. However, this average has decreased by 23.53% from the previous average price target of $4.25.

Portfolio Pulse from Benzinga Insights

September 06, 2023 | 3:00 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 10:24 am

IceCure Medical Ltd. (NASDAQ:ICCM) has received regulatory approval from the Brazilian Health Regulatory Agency for its ProSense Cryoablation System. The company expects $6.6 million in sales in the Brazilian market over the next five years. The ProSense system is a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal. The approval is expected to translate into near-term revenues due to strong demand in Brazil, which has an urgent need for minimally invasive cancer treatments.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.